

25 June 2018

ASX Announcement

Pentrox approved in Portugal and Switzerland.

Medical Developments International Limited (ASX: MVP) is delighted to announce that Pentrox has been approved for sale in Switzerland and Portugal.

MVP CEO, Mr. John Sharman said, "The roll out of Pentrox across Europe continues. We are delighted to have received the approval from Switzerland which is not part of the EU and therefore conducted its own independent assessment of Pentrox. We expect sales to commence in these markets during FY19."

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 (0) 414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
+61 (3) 9547 1888





About Pentrox

Pentrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Pentrox has been used safely and effectively for more than 40 years in Australia with excess of 5.0 million units sold. There is growing interest in Pentrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.